Pembrolizumab plus olaparib vs enzalutamide or abiraterone in patients with metastatic castration-resistant prostate cancer who experienced progression on chemotherapy: phase 3 KEYLYNK-010 study

被引：0
|
作者：
Yu, Evan [1 ]
Park, Se Hoon [2 ]
Huang, Yi-Hsiu [3 ]
Bennamoun, Mostefa [4 ]
Xu, Lu [5 ]
Kim, Jeri [5 ]
Antonarakis, Emmanuel [6 ]
机构：
[1] Univ Washington, Seattle, WA 98195 USA
[2] Samsung Med Ctr, Seoul, South Korea
[3] Taipei Vet Gen Hosp, Taipei, Taiwan
[4] Inst Mutualiste Montsouris, Paris, France
[5] Merck & Co Inc, Kenilworth, NJ USA
[6] Johns Hopkins Univ, Baltimore, MD USA
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2019年 / 7卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P390
引用
收藏
页数：2
相关论文
共 50 条
  • [41] CYCLONE 2: A phase 3 study of abemaciclib with abiraterone in patients with metastatic castration-resistant prostate cancer
    Smith, Matthew Raymond
    Piulats, Josep M.
    Todenhofer, Tilman
    Lee, Jae-Lyun
    Arija, Jose Angel Arranz
    Mazilu, Laura
    Azad, Arun
    Alonso-Gordoa, Teresa
    McGovern, Ursula Brigid
    Choudhury, Atish Dipankar
    Ye, Dingwei
    Suzuki, Hiroyoshi
    Mckay, Rana R.
    Ades, Steven
    Flechon, Aude
    Pieczonka, Christopher Michael
    Hulstijn, Maarten
    Lithio, Andrew
    Nacerddine, Karim
    Agarwal, Neeraj
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [42] Economic Outcomes in Patients with Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate Plus Prednisone
    Krishnan Ramaswamy
    Stanislav Lechpammer
    Jack Mardekian
    Ahong Huang
    Neil M. Schultz
    Rickard Sandin
    Li Wang
    Onur Baser
    Daniel J. George
    Advances in Therapy, 2020, 37 : 2083 - 2097
  • [43] Pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer progressing on enzalutamide: cohorts 4 and 5 of the phase 2 KEYNOTE-199 study
    Graff, Julie N.
    Hoimes, Christopher J.
    Gerritsen, Winald R.
    Vaishampayan, Ulka N.
    Elliott, Tony
    Hwang, Clara
    ten Tije, Albert J.
    Omlin, Aurelius
    McDermott, Raymond S.
    Fradet, Yves
    Tagawa, Scott T.
    Kilari, Deepak
    Ferrario, Cristiano
    Uemura, Hiroji
    Jones, Robert J.
    Fukasawa, Satoshi
    Peer, Avivit
    Niu, Cuizhen
    Poehlein, Christian H.
    Qiu, Ping
    Suttner, Leah
    de Wit, Ronald
    Schloss, Charles
    de Bono, Johann S.
    Antonarakis, Emmanuel S.
    PROSTATE CANCER AND PROSTATIC DISEASES, 2024,
  • [44] Switch from abiraterone plus prednisone to abiraterone plus dexamethasone at asymptomatic PSA progression in patients with metastatic castration-resistant prostate cancer
    Fenioux, Charlotte
    Louvet, Christophe
    Charton, Emilie
    Rozet, Francois
    Ropert, Stanislas
    Prapotnich, Dominique
    Barret, Eric
    Sanchez-Salas, Rafael
    Mombet, Annick
    Cathala, Nathalie
    Joulia, Marie-Liesse
    Molitor, Jean-Luc
    Henriques, Julie
    Bonnetain, Franck
    Cathelineau, Xavier
    Bennamoun, Mostefa
    BJU INTERNATIONAL, 2019, 123 (02) : 300 - 306
  • [45] Cardiovascular Risks and Survival with Abiraterone vs Enzalutamide in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer in Germany: AVENGER Study
    Axel S. Merseburger
    Eugen Dornstauder
    Carsten-Henning Ohlmann
    Armen Aprikian
    Sophia Junker
    Philipp Hahn
    Andrew Chilelli
    Matthias Stoelzel
    Alexis Serikoff
    Stefan G. Spitzer
    Advances in Therapy, 2025, 42 (4) : 1919 - 1934
  • [46] PEMBROLIZUMAB PLUS ENZALUTAMIDE IN ABIRATERONE-PRETREATED PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: UPDATED RESULTS FROM KEYNOTE-365 COHORT C
    Yu, Evan Y.
    Fong, Peter
    Piulats, Josep M.
    Appleman, Leonard
    Conter, Henry
    Feyerabend, Susan
    Shore, Neal
    Gravis, Gwenaelle
    Laguerre, Brigitte
    Gurney, Howard
    Retz, Margitta
    Romano, Emanuela
    Mourey, Loic
    de Bono, Johann S.
    Kam, Audrey
    Emmenegger, Urban
    Wu, Helen
    Schloss, Charles
    Poehlein, Christian
    Berry, William
    JOURNAL OF UROLOGY, 2020, 203 : E368 - E368
  • [47] ABIRATERONE ACETATE VERSUS ENZALUTAMIDE FOR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER POST CHEMOTHERAPY: COST EFFECTIVENESS ANALYSIS
    He, J.
    Li, T.
    Saadi, R.
    VALUE IN HEALTH, 2013, 16 (07) : A411 - A411
  • [48] KEYNOTE-921: Phase III study of pembrolizumab (pembro) plus docetaxel and prednisone for enzalutamide (enza)- or abiraterone (abi)-pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
    Petrylak, D. P.
    Li, B.
    Schloss, C.
    Fizazi, K.
    ANNALS OF ONCOLOGY, 2019, 30 : 351 - 351
  • [49] PROfound: Phase III study of olaparib versus enzalutamide or abiraterone for metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations
    Sandhu, S. K.
    Hussain, M.
    Mateo, J.
    Fizazi, K.
    Saad, F.
    Shore, N.
    Chi, K.
    Sartor, O.
    Agarwal, N.
    Olmos, D.
    Thiery-Vuillemin, A.
    Twardowski, P.
    Mehra, N.
    Goessl, C.
    Kang, J.
    Burgents, J.
    Wu, W.
    Kohlmann, A.
    Adelman, C.
    de Bono, J.
    ANNALS OF ONCOLOGY, 2019, 30
  • [50] THE CARDIOVASCULAR EFFECT OF ABIRATERONE AND ENZALUTAMIDE AMONG VETERANS AFFAIRS' METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS
    Baser, O.
    Baser, E.
    Samayoa, G.
    VALUE IN HEALTH, 2024, 27 (06) : S4 - S4
12345